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A B S T R A C T
A database of 91 chemicals with published data from both transgenic rodent mutation (TGR) and rodent comet
assays has been compiled. The objective was to compare the sensitivity of the two assays for detecting geno-
toxicity. Critical aspects of study design and results were tabulated for each dataset. There were fewer datasets
from rats than mice, particularly for the TGR assay, and therefore, results from both species were combined for
further analysis. TGR and comet responses were compared in liver and bone marrow (the most commonly
studied tissues), and in stomach and colon evaluated either separately or in combination with other GI tract
segments. Overall positive, negative, or equivocal test results were assessed for each chemical across the tissues
examined in the TGR and comet assays using two approaches: 1) overall calls based on weight of evidence (WoE)
and expert judgement, and 2) curation of the data based on a priori acceptability criteria prior to deriving final
tissue specific calls. Since the database contains a high prevalence of positive results, overall agreement between
the assays was determined using statistics adjusted for prevalence (using AC1 and PABAK). These coefficients
showed fair or moderate to good agreement for liver and the GI tract (predominantly stomach and colon data)
using WoE, reduced agreement for stomach and colon evaluated separately using data curation, and poor or no
agreement for bone marrow using both the WoE and data curation approaches. Confidence in these results is
higher for liver than for the other tissues, for which there were less data. Our analysis finds that comet and TGR
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generally identify the same compounds (mainly potent mutagens) as genotoxic in liver, stomach and colon, but
not in bone marrow. However, the current database content precluded drawing assay concordance conclusions
for weak mutagens and non-DNA reactive chemicals.
1. Introduction
In the early decades of regulatory genotoxicity testing, the most
commonly used in vivo somatic cell tests supported by the Organisation
for Economic Co-operation and Development (OECD) guidelines only
examined effects in bone marrow, namely induction of chromosomal
aberrations (CA; OECD Test Guideline [TG] 475, [1]) or micronuclei
(MN; OECD TG 474 [2]). The mouse spot test (OECD TG 484 [3]) was
available to measure mutations in different tissues, but was performed
in a limited number of laboratories and used large numbers of animals;
TG484 was deleted in 2014. When the unscheduled DNA synthesis
(UDS) test was developed [4], it allowed for the detection of genotoxic
effects in rodent liver. This test was also developed into an OECD
guideline (OECD TG 486 [5]) and was widely used to supplement the
bone marrow MN and CA assays, being particularly useful at detecting
hepatocarcinogens. However, tests to measure genotoxic effects in
other tissues were not widely available.
In recent years, two test systems that allow determination of gen-
otoxic effects in multiple tissues have been developed into OECD
guidelines – the transgenic rodent mutation (TGR) assay, originally
adopted in 2011 but updated in 2013 (OECD TG 488, [6]) and the in
vivo alkaline comet assay (OECD TG 489, [7]). The development of the
TGR OECD guideline was supported by the publication of Lambert et al.
[8] and the OECD Detailed Review Paper [9], and for the comet assay
by a collaborative multi-laboratory validation trial (see [10,11]). Both
assays have their strengths and limitations:
• The comet assay is an “indicator” test, as not all strand breaks will
necessarily result in mutation, whereas the TGR assay measures an
“apical” endpoint, i.e. a mutation.• The comet assay can be conducted in species and strains routinely
used for regulatory testing, and can therefore be integrated in other
in vivo toxicity tests, which has the advantage of reducing animal
usage. However, by its very nature, the TGR assay uses specific,
genetically modified rodent strains, which are not always readily
available and can be costly.• In the TGR assay, virtually any tissue can be taken and frozen for
subsequent analysis whereas, it is preferable to analyse fresh tissue
in the comet assay [12,13]. Currently there are no recommended
protocols for the comet assay in frozen tissues, although laboratories
are working on improving the reliability of data from frozen tissues,
including germ cells (see [14,15]).
Mutations in germ cells can be readily detected in the TGR assay
with certain protocol modifications [16], whereas the standard alkaline
comet assay is not recommended for measurement of genotoxic effects
in mature germ cells. As indicated in TG 489, the protocol for con-
ducting the alkaline comet assay in sperm requires further standardi-
zation [12]. Furthermore, the recommended exposure regimen and
sample collection in the guideline is not adequate for assessing geno-
toxicity in mature sperm.
Whilst the TGR and comet assays are available for measuring gen-
otoxic effects in multiple rodent tissues, there has been no systematic
comparison of their performance in detecting genotoxicity per se. A
working group of the Genetic Toxicology Technical Committee (GTTC),
part of the Health and Environmental Sciences Institute (HESI), was
therefore established to contribute to resolving this deficiency. This
manuscript describes the establishment of a database containing 91
chemicals with published TGR and in vivo comet assay data in at least
one common tissue, and presents the outcome of various analyses
addressing the above question. The results of the analysis may impact
regulatory toxicity testing, although this database is relatively small
and additional studies are needed to refine the comparison and further
clarify the sensitivity and specificity of TGR and comet assay results. A
key question the working group wished to address was whether it is
necessary to follow up a chemical that has been shown to be mutagenic
in vitro with an in vivo gene mutation assay (TGR test), or whether it
might be equally acceptable to conduct an in vivo comet assay. Creation
of this database is a first step towards answering that and many other
outstanding questions about how best to use these assays.
2. Construction of the database
As a starting point, the TRAiD (Transgenic Rodent Assay
Information Database [8]; this can be accessed by sending a request to
Dr Paul A. White, Health Canada, at paul.white@canada.ca), a com-
prehensive database of TGR dose-response data, was examined. The
TRAiD contains thousands of experimental records of transgenic mu-
tation results from different experimental treatments (chemicals, ra-
diation, pharmaceuticals, infectious agents, and mixtures), the majority
of which were conducted in the 1990s and early 2000s before the
standardization of study design when OECD TG 488 was first published
in 2011 [6]. The TRAiD database that was used for this exercise (v. 7.0,
updated September 2015) was originally compiled by Health Canada,
has been updated with papers published since 2011, and has been
carefully reviewed by members of the GTTC. Chemicals in the updated
TRAiD database that had been tested in the in vivo comet assay were
selected for comparative analysis, but alternative sources were also
used to construct the database. Additional in vivo comet assay data
available from previous database publications [17–19], along with in-
formation from the following websites, were used:
• NTP (https://ntp.niehs.nih.gov)• PubMed (https://www.ncbi.nlm.nih.gov/pubmed)• Toxline (https://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?TOXLINE)• CCRIS (https://toxnet.nlm.nih.gov/newtoxnet/ccris.htm)• European Chemicals Agency (https://echa.europa.eu)• European Food Safety Authority (EFSA, www.efsa.europa.euwww.
efsa.europa.eu).
During the search additional chemicals were identified that had
both TGR and in vivo comet data, and these were added to the database.
Where data were available on different forms of the same chemical (e.g.
free base and salt) the results were combined into a single entry, since
in aqueous biological systems it would be expected that the different
forms would behave in a similar way. This was done for:
• Diepoxybutane/1,2,3,4-diepoxybutane/1,2,3,4-DL-diepoxybutane• Hydrazine, hydrazine monohydrate, hydrazine sulfate, and hy-
drazine 2HCl• 2,6-Diaminotoluene (free base and 2HCl salt)• Sodium saccharin/saccharin• 2-Amino-3-methylimidazo[4,5-f]quinoline (IQ - free base and HCl
salt)• 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhiP - free base
and HCl salt)• o-Anisidine (free base and HCl salt)• Aristolochic acids I and II (and sodium salt)• Bleomycin/bleomycin HCl/bleomycin sulphate• Cyclophosphamide (free base and monohydrate)
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• 2,4-Diaminotoluene (free base and 2HCl salt)• Procarbazine/procarbazine HCl• 4-Aminobiphenyl (free base + HCl salt)• Phenobarbital/phenobarbital sodium.
Initially the group identified 92 chemicals for which there were data
from both comet and TGR assays in at least one tissue. The chemicals
were then divided up amongst 21 workgroup members for more in-
depth searching and analysis. Through this process additional pub-
lications were found and added to the data entry spreadsheets. Detailed
evaluations of each publication were made and tabulated in one of
approximately 20 columns in the data entry spreadsheets. Each column
prompted entry of data or comments on key aspects of methodology
such as numbers of animals, dose levels, dose duration, sampling times,
quality of the data, and interpretation of the results. After the initial
data entry, each sheet was reviewed by alternate co-authors to mini-
mise bias and ensure consistency across chemicals. The TGR and comet
data entry spreadsheets are shown respectively in Supplementary
Tables 1 and 2. When sorting through the compiled results, only 91
chemicals, shown in Supplementary Table 3, had data for both end-
points, in at least one common tissue. 2,3-epoxypropyl neodecanoate
had dropped out of the comparison as there were only alkaline elution
(and not comet) data available.
3. Methods of analysis of the database
Following the quality control steps described above, two different
approaches were considered to evaluate the data collected in the da-
tabase. In the first approach, one experienced individual reviewed all of
the collected data and allocated overall calls based on weight of evi-
dence (WoE) and expert judgement. These overall calls were applied to
each set of comet or TGR results in each tissue to derive tissue specific
calls, which were subsequently reviewed by the entire workgroup. We
labelled this the” WoE approach”. In the second approach, teams of
experienced individuals developed a priori acceptability criteria and
then reviewed each set of comet and TGR results, and only derived the
tissue specific calls on data that met the acceptability criteria. We la-
belled the second approach the “data curation approach”. An example
of the differences in the two approaches is that some data which were
used in the WoE approach but given low weight were excluded in the
data curation approach. The two approaches are described in more
detail below.
3.1. Approach based on all collected data using weight of evidence (WoE)
and expert judgement
The results for all 91 chemicals in each of the two assays were
summarised as a brief narrative shown in Supplementary Table 3 in the
columns headed “Summary of results” (columns G and V). There were
fewer results in rats than in mice, particularly for the TGR assay where
the vast majority of results were in mice:
• For TGR, 13 chemicals were studied in rats only, 60 were in mice
only, and 18 were in both rats and mice;• For comet, 16 chemicals were studied in rats only, 23 in mice only,
and 52 in both rats and mice.
Therefore, in order to provide sufficient data for comparison, and
since either species is acceptable for in vivo genotoxicity testing, data
from rats and mice were combined, and the same rationale was applied
to data obtained in males and females. The most widely studied tissues
in both assays were liver and bone marrow. However, there were sev-
eral reasons (given below) to also look at responses in various segments
of the GI tract:
• OECD guideline 488 [6] says “The rationale for tissue collection should
be defined clearly. Since it is possible to study mutation induction in
virtually any tissue, the selection of tissues to be collected should be based
upon the reason for conducting the study and any existing mutagenicity,
carcinogenicity or toxicity data for the chemical under investigation.
Important factors for consideration should include the route of admin-
istration (based on likely human exposure route(s)), the predicted tissue
distribution, and the possible mechanism of action. In the absence of any
background information, several somatic tissues as may be of interest
should be collected. These should represent rapidly proliferating, slowly
proliferating and site of contact tissues”.• OECD guideline 489 [7] says “In some cases examination of a site of
direct contact (for example, for orally-administered substances the
glandular stomach or duodenum/jejunum, or for inhaled substances the
lungs) may be most relevant.”• In ECHA’s 2015 REACH progress report [20] it is stated that the
default requirement for oral comet assays was to “….analyse two site-
of-contact tissues (glandular stomach and duodenum/jejunum), in ad-
dition to liver”.• EFSA’s Minimum Criteria for the acceptance of in vivo alkaline
Comet Assay Reports [21] requires one site of contact tissue (e.g.
stomach or duodenum) in addition to liver to be examined by de-
fault in the assay, due to the primary route of human exposure for
chemicals in food.
Most GI tract results were in stomach and colon but there were also
a few results in oesophagus, forestomach, ileum, jejunum, duodenum,
caecum, and small intestine. Therefore, since the objective of the OECD,
ECHA and EFSA statements above seemed to be to assess site-of-contact
effects, it was decided to look at responses in any section of the GI tract
in this WoE comparison of TGR and comet responses. In many cases, the
same chemical was reported to give different results in different pub-
lications in the same tissue, or had been tested by different routes of
administration. We are as yet unable to determine the reasons for di-
vergent results within the same tissue for an assay. Differences in length
of dosing, dose level, sampling time, or route of administration could
have been responsible but we could not precisely associate these factors
with individual cases of divergent results. Therefore, a WoE evaluation
using expert judgement was employed to derive overall calls for the
TGR and comet assay responses in liver, bone marrow and GI tract, and
is described below. These overall calls were made initially by a single
individual and the overall analysis was then reviewed by the entire
workgroup. These overall calls fell into four categories, positive (+),
negative (-), equivocal (E) and inconclusive (I), and are shown in the
columns identified as “WoE” in Supplementary Table 3.
The following principles were applied in arriving at these overall
WoE calls. Although the methods described in OECD test guidelines are
considered sufficiently robust that negative results can be accepted with
confidence, many of the published TGR and comet assay studies in the
database were conducted before the respective OECD guidelines were
adopted. Even studies published since the guidelines were adopted
often deviate from the recommended experimental designs. Moreover,
many of the published studies were designed to answer questions other
than those for which the regulatory Test Guidelines were developed.
Thus, data from studies which were fit for their intended purpose were
not always easy to compare to the other studies in our database for the
purpose of our analyses. Therefore, scientific judgement had to be ap-
plied to the data in order to decide whether the results could be ac-
cepted as valid. For example, a clear positive result from a study that
used a shorter dosing period, fewer sampling times, or smaller group
sizes could be more easily accepted as positive than a negative result
from similar non-guideline study designs. Also, negative results from a
recent comet or TGR study conducted to current OECD guidelines were
considered more conclusive than a negative result from a study that did
not comply with current test guidelines or previously recommended
best practices (e.g. [22,23]), or from studies that contained little in-
formation on the test methods used. Negative results from such studies
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where the robustness of the protocol was questionable were therefore
allocated an “inconclusive” call. Where conflicting results were re-
ported in the different publications, the numbers of+ and – calls were
not considered as important as the quality and robustness of the in-
dividual tests. Consideration was also given to whether the results had
been obtained in different studies or from different publications. In
those cases where the same study results were reported in different (e.g.
original and review) publications, the results were considered as a
single entry.
For the overall calls by the WoE approach the following criteria
were adopted:
• An overall positive (+) call was given if: (1) there was only one
study available and it provided clear evidence of a positive response
regardless of whether it was conducted in mice or rats, males or
females.; (2) there was clear weight of evidence from more than one
study (i.e. multiple positive results outweighing a small number of
negative results) or (3) if a substance was positive in one species or
sex and negative in the other, and it was clear that systemic ex-
posures (e.g. higher dose levels, evidence of target organ toxicity in
the positive study) would have been greater in the positive than in
the negative study. Where authors had reported a “weak positive”
response, these were considered positive.• An overall negative (-) call was given when the experimental design
met or was close to the requirements of the current OECD guide-
lines, or recommended best practices (e.g. [22,23]) were fulfilled,
and there was no evidence of a positive or equivocal response in any
study. A negative call was made only if there was evidence that the
test substance would have reached the target tissue, otherwise it was
considered inconclusive (see below).• An overall equivocal (E) call was given if results were ambiguous,
doubtful, inconsistent (e.g. positive and negative results) within a
study, or unclear (e.g. a dose-related increase in effect but the
magnitude of response did not achieve statistical significance or
exceed normal control ranges, and no independent repeat experi-
ment was done to verify the response and produce a clear conclu-
sion). An “E” call was also used where there were both positive and
negative findings across different studies of apparently acceptable
quality and validity, and where the weight of evidence did not allow
a clear positive or negative overall outcome to be concluded.• An overall inconclusive (I) call was given in the case of negative or
unclear results, where no firm conclusion could be made in terms of
the requirements of the current OECD guidelines or recommended
best practices. This applied most frequently to negative TGR studies
where animals had only been dosed for a few days (instead of the
recommended 28 days), or where negative results were obtained but
there was no proof of target cell exposure in vivo (for example, no
analysis of test substance in blood or tissue and no target organ
toxicity). Most comet studies were performed to designs that were
close to the current OECD TG, and so there were fewer inconclusive
calls. It was concluded that an “I” call should be considered as an
inadequate test and treated as “no valid data”.
The vast majority of GI tract results were from stomach and colon,
and these were analysed separately with the data curation methodology
(see section 3.2). However, for this WoE analysis it was assumed that
the objective of investigating responses in the GI tract was to determine
site-of-contact effects. Thus, although the majority of published results
were in stomach and colon, results from other segments of the GI tract
(oesophagus, forestomach, duodenum, jejunum, ileum, caecum, small
intestine, and large intestine) were also considered valid for site-of-
contact effects. Therefore, in this WoE approach, results from all of the
different segments of GI tract were combined for the purposes of
comparison. The overall calls described above therefore had to be
modified slightly for GI tract as follows:
• Overall positive (+) calls were given where one or more segments
of the GI tract gave a positive result in more than one publication,
even if some other segments of the GI tract that were studied less
frequently were negative.• An overall positive (+) call was also given if GI tract tissues were
positive using oral administration but negative using intraperitoneal
(i.p.) administration (since oral administration would generally re-
sult in greater and more direct exposure to the cells that are scraped
from the inner lining of the GI tract to obtain samples for the comet
assay; moreover, oral gavage is preferred over i.p. administration in
the OECD test guideline). However, if the only data were from i.p.
administration, the positive GI tract results were accepted.• Equivocal (E) calls were given as described above for bone marrow
and liver data if results from a single study were ambiguous,
doubtful, inconsistent or unclear. Equivocal calls were also given
where there were approximately equal numbers of positive and
negative results between studies of the same GI tract segment con-
ducted in different laboratories or in different segments of the GI
tract (e.g. equal numbers of positive results in stomach and negative
results in colon) whether from the same or from different labora-
tories. For example, 2-acetylaminofluorene was positive in colon of
mice but negative in stomach of mice by oral dosing, positive in
stomach and colon of mice by i.p. dosing, but negative in stomach of
rats by both oral and i.p. dosing, and so an overall call of E was
allocated. This pattern of mixed results was found more frequently
with the comet assay, but less so for the TGR assay since there were
few chemicals with TGR data in both stomach and colon.• An overall negative (-) call was given when all GI tract tissues
evaluated were negative, even if only the i.p. route of administration
was used, since i.p. administration would usually be expected to
result in some GI tract exposure either by absorption into the hepatic
portal system followed by enterohepatic recirculation, or by sys-
temic bioavailability as a result of by-passing first-pass metabolism
(see [24]).• As described above, inconclusive (I) calls were given, for example,
where treatment duration was too short in the TGR but gave a ne-
gative result, or, in one case, where a negative result was reported
for a comet assay that used only a single dose level.
As in any evaluation, equivocal (E) responses form a unique cate-
gory. It can be argued that, because the response is not clearly negative,
“E” calls should be included in the positive response category.
However, it can also be argued that they should be excluded from the
positive category because they did not meet the established criteria for
a positive response. For the purpose of the WoE approach, “E” calls
were considered as “no valid data” and therefore excluded from the
analysis. Since inconclusive calls would not contribute to a comparison
of TGR and comet responses they were also excluded. Thus, WoE ana-
lyses were made on overall “+” and “- “calls only.
3.2. Step-wise approach using detailed data curation methodology
3.2.1. Step 1: verifying quality of the database
As described above, the data used for this exercise were collected
from all available sources in the literature, and it was evident that the
quality of some of the studies was questionable. Hence, a detailed
evaluation of the quality of the study protocol and the data in each
paper across all 91 chemicals was conducted prior to accepting the data
into the curated database. This was achieved by objectively assigning a
numerical “quality” score to each study, using the a priori quality cri-
teria listed in Table 1. These criteria were developed independently for
each assay although consistency across assays was intended. These
quality scores were applied equally across all data in the database using
evaluation criteria developed prior to considering the impact of omit-
ting a particular study from the overall analysis. This ensured that only
selected high-quality data in the database would be used for the
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allocation of overall calls and subsequent analyses.
The assignment of quality scores to the TGR and comet studies was
carried out separately by two independent expert groups. For the TGR
expert working group, two teams of experts reviewed and scored all
studies. Any scoring discrepancies were discussed by all members of the
TGR expert group and a consensus call was reached for all studies. For
the comet expert working group, two individuals went through the
database and independently assigned quality scores. When there was a
discrepancy, the consensus call was reached by the entire expert
working group.
To assign quality scores, the criteria in Table 1 must have been met
for the study being evaluated. Studies given higher quality scores met
the criteria for all lower categories as well. For example, route of ad-
ministration must be stated for studies scored both 2 and 3. A list of the
final quality scores used in the databases is presented in Fig. 1. The final
quality score for each paper was then assigned to the responses in each
reported tissue. For example, for a quality 2 paper that had positive
liver and negative bone marrow findings, the liver would be considered
positive. However, bone marrow would be considered inconclusive.
It should be noted that the authors were aware that tissue toxicity
may be a confounding factor. For chemicals that induced positive re-
sponses across different dose levels in the same study, or where the
results across different papers in the same tissue agreed with one an-
other, we did not believe cytotoxicity was likely to be a confounding
factor. However, where the publications did contain histological or
other evidence of cytotoxic effects, and this could have confounded a
positive response, particularly if this was only at the top dose level, the
findings were downgraded in that tissue.
The assignment of the a priori quality criteria listed in Table 1, and
the application of these scores as described above, led to the following
actions:
• Score of 0: Unusable; no data, abstract only, or incorrect assay.• Score of 1: Problematic; correct assay but methodology limitations
prevented study acceptance.• Score of 2: Sub optimal; positive test results are considered valid,
but limitations in study design diminished the reliability of negative
test results.• Score of 3: Valid; all test results are reliable. The studies were
conducted using a protocol which conformed to standardised
criteria developed by the workgroup or in compliance with the
applicable OECD test guideline.
3.2.2. Step 2: determining tissue-specific results from discordant data
Of the 91 chemicals that had both comet and TGR data, in 28 in-
stances, the comet assay produced discordant results in specific tissues.
Differences in rodent species, dose level, sex, dose duration, and/or
route of administration were among the potential causes of dichot-
omous results. With the exception of dicyclanil1, these differences were
not weighted in our evaluation when making final calls on tissue spe-
cific results. This was justified by the understanding that a laboratory
that evaluates a previously untested chemical would be unlikely to
know this information while planning an in vivo genotoxicity study.
Therefore, when discordant results were observed, the following cri-
teria were employed to determine an overall tissue-specific result:
Table 1
Assignment of quality scores for comet and TGR papers using pre-determined criteria.
Quality Score A Priori Maximum Scoring Criteria
0 Papers that did not present data.
Unusable Human data from occupational/epidemiologic sources.C
Alkaline elution methods were used.C
Data generated from in vitro or ex vivo dosing.C
1 Methods were omitted.
Problematic (not used in the curated analysis) Summary data, abstract, or duplicated data already reported.
Group size was omitted or < 3.
Lack of concurrent vehicle controls.
Frequency and/or dose duration omitted.
Unspecified route of administration.
Potential confounding cytotoxicity.C
Most of the fields on the data checking sheets were blank.
Number of nuclei scored omitted or <50 per animal.C
Data obtained at an atypical necropsy timepoint (e.g., 8 hours).C
2 Highest dose(s) inadequate to demonstrate an effect.
Trust positive Results (negative results inconclusive) Only a single dose used.TGR
Too few repeat doses (< 28 daysTGR or no short or long exposureC).
Unverifiable data cited in the review of Sasaki et al. (2000).C
Sample time after last dose not stated or not close to 3 days.TGR
3 Methods compliant with the OECD TG, or recommendations from
Trust Results the JaCVAM (pre)validationCor IWGT (Tice et alC).
C Specific to comet papers.
TGR Specific to TGR papers.
Fig. 1. Literature quality of all of the available comet and transgenic rodent
assay data in the literature. A total of 91 chemicals with data in the same tissue
(s) across both assays were included in the final database.
1 Dicyclanil was a special case because of the unusually rich dataset which
consistently shows a sex difference. Not only do cancer bioassays demonstrate
this [25], but our database captured comet and TGR data in both sexes that
were consistent with the sensitivity of females and not males.
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• Papers with a quality score of 0 and 1 were not considered when
determining overall tissue calls.• Papers with a quality score of 2 were considered in the case of po-
sitive results only. Negative results from those papers were called
inconclusive and not considered.• For a clear positive or negative response, the majority (at least 70%)
of papers of acceptable quality had the same result in that tissue.• For remaining chemicals, on a tissue by tissue basis, equivocal re-
sults were assigned if the above criteria were not met. This de-
creased the number of chemicals with definitive results in both as-
says from 35 to 33 for liver, 16 to 10 for bone marrow, and 19 to 13
for GI tract (specifically, 5 chemicals had stomach data in both as-
says, and 8 chemicals had colon data in both assays).
For the chemicals with equivocal calls, it is unclear whether the
assays were able to detect genotoxicity in that particular tissue. As
mentioned, additional testing using current scientific protocols or al-
ternate dose levels could clarify the genotoxic potential of these che-
micals in the tissues studied. Hence, the analysis was conducted 3 se-
parate ways. First, only bona fide positive and negative results were
compared, mimicking the WoE approach. Then equivocal data were
considered either positive or negative, to “bracket” the outcome of such
further investigations.
Although the GI tract was evaluated as a single site of contact tissue
using the WoE approach, it was decided to attempt to analyse stomach
and colon separately, after data curation, for the following reasons:
• For TGR, only 3 chemicals were studied in both stomach and colon,
which is too few to draw conclusions on concordance of response
across tissues.• For comet, 43 chemicals were studied in both stomach and colon
and only 29 (67%) were concordant (both tissues positive or nega-
tive).
The results mentioned above for stomach and colon exemplify the
diverse anatomical and physiological properties of these tissues, i.e. the
parenchymal cells are different between the two tissues, chemicals may
be modified by the time they reach distal GI tissue impacting actual
exposure levels, and duration of exposure due to enterohepatic circu-
lation may be different in the two compartments. Hence, the comet and
TGR subgroups analysed stomach and colon separately using the cu-
rated database and did not try to combine stomach and colon results
into a single category such as “GI tract”.
3.3. Statistical approaches
Since the primary question that stimulated the compilation and
analysis of this database was “do the TGR and comet assays detect
positive responses for the same chemicals (i.e. do they have the same
sensitivity to genotoxicants)”, then sensitivity is the analogous de-
scriptive statistic to evaluate. The TGR results were therefore taken as
the reference point (as it measures an apical endpoint), and for each of
the selected tissues (liver, bone marrow, GI tract or separately stomach
and colon) the proportion of TGR-positive chemicals that were also
positive in the comet assay (i.e. sensitivity) was determined; 95%
confidence intervals were calculated using the modified Wald method
[26].
For the WoE analysis, only overall positive and overall negative
results were compiled into 2×2 tables. Overall calls of E and I were
excluded. This same approach was utilized for the curated data ana-
lysis. However, after curation many positive and negative results had
moved to equivocal due to their quality scores. Hence, equivocal results
were included in a sub-analysis, where they were considered either
positive or negative for each tissue, except for colon, which had no
equivocal data.
The analysis of the 2× 2 tables was carried out in the same way for
both WoE and curated data approaches. There is no single statistic that
can capture all the aspects of a 2×2 table. The traditional way to as-
sess agreement between two different measures (or scorers) has been to
use Cohen's kappa statistic [27]. However, it is well known that kappa
has limitations, especially when the marginal totals of the tables are not
symmetrical (see [28]), as is the case for this data set, which has a high
prevalence of positive results in both assays and very few negative re-
sults in either assay (see tables of results discussed below). Flight and
Julious [28] note that: (1) for high values of concordance, low values of
kappa can be recorded; and (2) asymmetric tables have a higher kappa
than symmetric tables (the kappa “paradoxes”). Gwet [29] developed
the AC1 statistic because of such limitations with the kappa. The AC1
between two or multiple raters is defined as the conditional probability
that two randomly selected raters agree given that there is no agree-
ment by chance. Flight and Julious [28] recommend using the Bias
Index (BI), the Prevalence Index (PI), MAK (maximum attainable
kappa) and the PABAK (the prevalence and bias adjusted kappa), and
argue that the PABAK [30] is less influenced by the prevalence and the
distribution of the marginal totals. They caution against relying on just
the kappa value which, in certain circumstances, can be low even when
there is good concordance, and instead recommend the use of all the
statistics in the interpretation. The PI is the difference between the
probability of each category occurring. From a standard 2× 2 table
(Table 2) it is calculated as PI = (a–d)/N. The lower the PI, the more
balanced the table. Thus, larger values of PI result in a larger proportion
of agreement than expected by chance and hence a smaller kappa value.
The BI is a measure of the difference in proportions of times each rater
classifies an object into category one. From a standard 2× 2 table
(Table 2) it is calculated as BI = (b–c)/N. Larger values of BI result in
larger values of kappa. PI and BI can help explain when the paradoxes
of kappa are likely to occur.
Therefore, as recommended by Flight and Julious [28], for each
2×2 table, sensitivity, PI, BI, kappa, PABAK and AC1 have been cal-
culated, and the agreement/disagreement between the different mea-
sures is discussed. There are a number of different categorisations of
agreements (and other measures of association) that can be applied to
these metrics. One categorisation that can be used to interpret the level
of agreement for kappa, which is applicable to AC1 [31] and should
therefore also be applicable to PABAK, was published by Landis and
Koch [32] and is shown in Table 3. Although these are useful categories
they should not be over interpreted. Moreover, it has been suggested
that these categorisations should be applied to the lower 95% con-
fidence levels of each statistic because that also takes into account the
size of the sample. It should be noted that for these types of statistics,
sample sizes ≤ 95 are small (which is the case here, as can be seen from
the tables to be discussed below), and therefore the confidence
Table 2
Standard 2× 2 table.
Cat. 1 Cat. 2 Total
Cat. 1 a b g1
Cat. 2 c d g2
Total f1 f2 N
Table 3
Interpretations of the kappa statistic (from
Landis & Koch, [32]).
Kappa Agreement
< 0.20 Poor
0.21-0.40 Fair
0.41-0.60 Moderate
0.61-0.8 Good
0.81-1.00 Very good
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intervals, which are calculated using n, are wide.
Power simulations were also performed with AC1, which, like kappa
and PABAK, ranges from -1 (complete disagreement between the 2
endpoints) through zero (no agreement) to +1 (complete agreement).
The null hypothesis for these power simulations is that AC1 is zero and
that there is no agreement. If there is very high agreement (e.g. near
100%) between two tests for the nature (e.g. genotoxicity) of a popu-
lation of chemicals then only small samples from this population are
needed to have a high (90%) probability of showing that an estimate of
the level of agreement from the sample is significantly different from
zero. If the 'true' level of agreement is lower, then larger sample sizes
are needed to have 90% power.
The simulations showed that if the comparisons between TGR and
comet were based on 11 observations, then there is 90% power that if
the true value of AC1 is different from zero it will be detected as sig-
nificant. As will be seen from the tables discussed below, with the ex-
ception of bone marrow (excluding equivocal calls), stomach, and colon
using curated data, there were definitive comparisons for at least 11
chemicals in each tissue. This means that there is a high probability
(> 90%) that if there is appreciable agreement between TGR and comet
it will be detected as being statistically significant. For instance, if the
association between the assays was good (e.g. AC1= 0.6), overall calls
from at least 25 chemicals in a tissue would be needed to provide 90%
power that the agreement differs from zero, and if the association be-
tween the assays was only moderate (e.g. AC1= 0.4), overall calls from
at least 60 chemicals in a tissue would have been needed to provide
90% power. When the association was very poor (e.g. AC1=0.06) then
sample sizes of over 4000 would be needed to have approximately 90%
power. It is reasonable to assume that similar power would be achieved
for the other statistics. It is therefore concluded that the majority of
datasets analysed had sufficient power to reject the null hypothesis
(that there was no agreement between the assays) when any of the
statistical approaches showed moderate to good agreement.
4. Results
4.1. Analysis of overall TGR and comet responses in liver, GI tract and bone
marrow based on all publications in the database using weight of evidence
(WoE) and expert judgement
The 2×2 tables for liver, GI tract and bone marrow are shown in
Table 4, with statistical analyses reported in Table 5. The following
comments can be made:
• The prevalence indices reflect the high number of positive results in
both TGR and comet assays, particularly in liver and GI tract.
Therefore, AC1 and PABAK analyses with corrections for prevalence
would be considered more informative than kappa alone.• The bias indices are low indicating no particular bias in these data
sets.• For liver and GI tract, the AC1 and PABAK statistics showed mod-
erate to good agreement based on the central estimates, but only
poor, fair or moderate agreement based on the lower confidence
limits. However, the sensitivity values for liver and GI tract were
high, even when the lower confidence intervals were considered.
This means that the comet assay shows very high agreement with
the TGR assay at detecting positive responses in liver and GI tract.• For bone marrow, there was poor agreement between comet and
TGR for each of the statistics – there was even some evidence of
disagreement based on the lower confidence limits – and the sen-
sitivity was low.
Chemicals for which overall calls of positive (+) or negative (-)
could be made for liver, GI tract and bone marrow are listed in Table 6.
There were overlapping data sets in liver for 35 chemicals, in GI tract
for 19 chemicals, and in bone marrow for 15 chemicals. As expected,
the number of chemicals with positive test results in TGR and/or comet
exceeds the number of chemicals with negative test results, particularly
for liver and GI tract. Whilst many concordant results were found across
different species, routes of administration, treatment times and sam-
pling times, which might be expected from a database containing so
many recognized genotoxicants with broad-ranging activity, such fac-
tors may also contribute to the observed discordant results. However,
with the small numbers of discordant results, and with such varying
protocols amongst the published papers, explanations of why data were
discordant are not possible at this time.
4.2. Impact of data curation on the database
Detailed results of the data curation are presented within the TGR
and comet databases in Supplementary Tables 1 and 2, respectively.
These tables include all the parameters captured during the initial data
checking exercises, the outcome of the experiment in each tissue sam-
pled, and the classifications made during the data curation.
The comet database has 471 lines of data, with each line reporting
results for one chemical in a single study of male or female test animals.
During curation of the database, studies were excluded from the ana-
lysis for a variety of reasons (Table 1). In a few cases, comet data de-
scribed in an abstract could not be confirmed based on reading the
entire paper. More often deficiencies in assay conduct or reporting led
to such low confidence in the validity of the results that they were
excluded. The curated comet database included 358 lines of data for the
91 chemicals. Data for 26 of the chemicals consisted of only a single
study. Removing almost a quarter of the data from the analysis had
minimal impact on the number of chemicals analysed. This was because
many of the studies removed for poor quality were of extremely potent
alkylating agents like cyclophosphamide or similarly potent mutagens,
and the remaining excluded studies were for chemicals for which there
were other, higher quality studies in the database. Analysing results
from multiple studies for a chemical in the database was not straight-
forward. For example, two lines of data could report results from two
experimental groups from the same experiment (e.g. 90-day repeat dose
protocol compared to 3-day exposure protocol both in the same species)
or from different laboratories using the same or different species. The
Table 4
Comparison of TGR and comet assay results using the WoE approach.
A: Liver Data
Liver TGR mutation (Mice and/or Rats)
Result + – Total
Comet (Mice and/or Rats) + 23 4 27
– 3 5 8
Total 26 9 35
B: GI Tract Data
GI tract TGR mutation (Mice and/or Rats)
Result + – Total
Comet (Mice and/or Rats) + 14 3 17
– 0 2 2
Total 14 5 19
C: Bone Marrow Data
Bone marrow TGR mutation (Mice and/or Rats)
Result + – Total
Comet (Mice and/or Rats) + 7 1 8
– 5 2 7
Total 12 3 15
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comet data were fairly evenly divided between rats (174/358, 49%)
and mice with a few studies in hamsters, guinea pigs, etc. The most
common routes of administration were oral/gavage (52%) and in-
traperitoneal injection (38%). Less common routes of administration
included drinking water/feed, dermal application, inhalation, in-
travenous injection, or intratracheal instillation of particles. Liver was
sampled in the majority of studies (68%); other commonly sampled
tissues included stomach (44%), bone marrow (40%), kidney (39%),
lung (35%), bladder (30%), brain (30%), colon (27%), and blood
(24%), with<4% of studies conducted in other tissues. After curation,
which led to the exclusion of certain poor quality studies, approxi-
mately 90 lines of data remained from studies conducted by Sasaki et al.
published between 1996 and 2003 (see Supplementary Table 3 for re-
ferences).
The TGR database has 525 lines of data, each line generally re-
porting results for one chemical in a single group of test animals.
Similar to comet data, during curation of the database, studies were
removed from the analysis for a variety of reasons (see Table 1). The
curated database included 404 lines of data for the 91 chemicals. As for
the comet database, removal of those data from the TGR database had
minimal impact on the number of chemicals analysed and for the same
reasons as above: there were many studies of potent alkylating agents
(various nitrosamines, ethyl- and methyl methanesulfonate) and other
potent genotoxicants, or of less potent chemicals all of which were also
represented in the database by higher quality studies. As mentioned, a
large fraction of the studies was conducted before protocols were
standardised by publication of the OECD Test Guideline, and many of
these consisted of< 28 days of dosing. Negative results from such
studies were interpreted as less reliable. Data were limited to only a
single study for 26 of the chemicals, the same number as for the comet
database. Unlike the comet data, the database consists mostly of data
generated from mice, as there were relatively little rat data (74/405,
18%) and transgenic guinea pigs, hamsters, etc., are not commercially
available. Routes of administration were more variable than for comet.
The most common routes of administration were intraperitoneal in-
jection (39%) with a relatively lower proportion by oral/gavage (24%),
and less so in drinking water (10%), and feed (17%). Liver was sampled
in the majority of studies (58%). Other tissues were sampled less fre-
quently for TGR mutations than for comets. Listed in the same order as
for comet in the preceding paragraph they include stomach (8%), bone
marrow (17%), kidney (13%), lung (19%), bladder (4%), brain (4%),
and colon (12%). Spleen (12%) was sampled much more often for TGR
mutations than for comets, as were testes and sperm, which were not
closely tracked in our analyses since they are difficult to evaluate using
the comet assay.
4.3. Analysis of overall TGR and comet responses in liver, stomach, colon
and bone marrow after database curation
Throughout the curation process, many calls switched either from
equivocal to positive or negative, or vice versa. There were no instances
in which a chemical that was judged as positive or negative using the
WoE approach had the call reversed (i.e. became negative or positive,
respectively) after data curation. Where there were multiple studies for
the same compound, the TGR study results were frequently in agree-
ment, and therefore there was only a single overall call of equivocal in
the curated TGR data set across all tissues. Conversely, there was less
agreement between different studies for the same chemical using the
comet assay, which resulted in 50 overall equivocal calls in the curated
comet data set across all tissues (see Supplementary Table 2 for details).
The 2× 2 tables for liver, stomach, colon and bone marrow using
positive and negative results are shown in Table 7. When equivocal
results were considered as either negative or positive, separate 2×2
tables were created (Table 8), and the statistical analyses across both
sets of data are reported in Table 9.
The following comments can be made when comparing definitive
positive and negative results:
• The prevalence indices reflect the high number of positive results in
both TGR and comet assays particularly in liver, stomach and colon.
Therefore, AC1 and PABAK analyses with corrections for prevalence
would be considered more informative than kappa alone.• The bias indices are low, indicating no particular bias in these data
sets.• For liver, stomach and colon, the AC1 and PABAK statistics showed
moderate to good agreement based on the central estimates, but
only poor, fair or moderate agreement based on the lower con-
fidence limits. However, the sensitivity values for liver, stomach and
colon were high, even when the lower confidence limits were con-
sidered. This means that the comet assay shows good agreement
with the TGR assay in detecting positive responses.• For bone marrow, there was very poor or no agreement between
comet and TGR for each of the statistics – there was even some
evidence of disagreement – and the sensitivity of the comet assay in
detecting TGR-positive responses in this tissue was low.
A list of chemicals for which overall calls of positive (+) or negative
(-) could be made for liver, stomach/colon, and bone marrow are listed
in Table 10. Due to attrition of lower quality data, the total number of
chemical comparisons was lower post data curation (than after WoE
evaluation), particularly when analysing stomach and colon as separate
tissues. Thus, in liver there were overall+ or - calls for 33 chemicals, in
stomach for 5 chemicals, in colon for 8 chemicals, and in bone marrow
for 10 chemicals. However, these numbers generally increased when E
Table 5
Statistical analyses of results for liver, GI tract and bone marrow (WoE approach).
Tissue Sensitivity#(95% CI) PI BI Kappa (95% CI) PABAK (95% CI) AC1 (95% CI)
Liver 0.82(0.70-0.97) 0.51 0.03 0.46c(0.13e-0.79) 0.60c(0.31d-0.83) 0.68b(0.44c-0.93)
GI tract 1.00(0.75-1.00) 0.63 0.16 0.50c(0.11e-0.88) 0.68b(0.37d-1.00) 0.77b(0.49c-1.00)
Bone marrow 0.58(0.32-0.81) 0.33 −0.27 0.17e(-0.25g-0.59) 0.20e(-0.33g-0.73) 0.28d(-0.29g-0.85)
PI= prevalence index.
BI= bias index.
CI= confidence interval.
a= very good agreement (0.81–1.00).
# = ability of the comet assay to detect TGR positives.
b = good agreement (0.61-0.80).
c = moderate agreement (0.41-0.60).
d = fair agreement (0.21-0.40).
e = poor agreement (< 0.20).
g = fair disagreement (-0.21 to -0.40).
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calls were counted as positive or negative (Tables 7 vs 8). Similar to the
WoE approach, the number of chemicals with positive test results in
TGR and/or comet exceeds the number of chemicals with negative test
results for liver, stomach and colon; however, there were an equal
number of positives and negatives for bone marrow. It should be noted
that induction of comet damage in bone marrow was detected least
frequently in a compilation of comet data with over 200 rodent carci-
nogens, almost all of which were tested in 8 tissues including liver,
stomach, colon and bone marrow [33]. This apparent insensitivity in
bone marrow may be due to the nature of this tissue as a haemato-
poietic tissue with a high cell turnover rate. DNA damage may cause
delayed cell cycle (particularly for high dose levels), whereas a stable
mutation may not. Hence, the analysis of bone marrow data may be
impacted by the inability of the standard comet assay to efficiently
detect DNA damage in that tissue. It is possible that sampling times for
the comet assay may need to be ‘optimized’ for bone marrow relative to
other tissues.
When analysing equivocal calls as either positive or negative the
following comments can be made:
• Considering the equivocal calls as positive results did not qualita-
tively change the statistical outcome for liver. Considering them
Table 6
Lists of chemicals with overall positive/negative results in both TGR and comet assays (WoE approach).
A: Liver
TGR +/ comet + (23) TGR +/comet – (3) TGR -/ comet + (4) TGR -/comet – (5)
1-Ethyl-1-nitrosourea 4-Aminobiphenyl (free base +
HCL salt)
3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5 H)-
furanone (AKA MX)
Allura Red AC (Food Red 40)
2,4-Diaminotoluene (free base and 2HCl salt) Chlorambucil Acetaminophen Chloroform
2-Acetylaminofluorene Methyleugenol Benzene Hydroquinone
2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) Ethyl acrylate Methylphenidate HCl
2-Amino-3-methylimidazo[4,5-f]quinoline (IQ - free base
& HCL salt)
Nitrite, sodium
5,9-Dimethyldibenzo[c,g]carbazole
Acrylamide
Aflatoxin B1
Aristolochic acids I and II (and sodium salt)
beta-Propiolactone
Cyclophosphamide (free base and monohydrate)
Cyproterone acetate
Dichlorvos
Dicyclanil
Ethyl methanesulphonate
Methyl methanesulphonate
N-Nitrosodiethylamine
N-Nitrosodimethylamine
N-Nitrosodipropylamine
N-Nitroso-N-methylurea
N-Nitrosopyrrolidine
Urethane
Wyeth 14,643
B: GI tract
TGR +/ comet + (14) TGR +/comet – (0) TGR -/ comet + (3) TGR -/comet – (2)
1-Ethyl-1-nitrosourea Chromium (hexavalent) Hydroquinone
2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhiP - free base & HCl salt) Ethyl acrylate Nitrite, sodium
2-Amino-3,4-dimethylimidazo[4,5-f]quinoline (MeIQ) N-Nitrosodimethylamine
2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx)
2-Amino-3-methylimidazo[4,5-f]quinoline (IQ - free base & HCL salt)
4-Nitroquinoline-N-oxide
7,12-Dimethylbenz[a]anthracene
Benzo[a]pyrene
beta-Propiolactone
C.I. Solvent yellow 3 (o-aminoazotoluene)
Methyl methanesulphonate
N-Methyl-N'-nitro-N-nitrosoguanidine
N-Nitroso-N-methylurea
Urethane
C: Bone marrow
TGR +/ comet + (7) TGR +/comet – (5) TGR -/ comet + (1) TGR -/comet – (2)
4-Nitroquinoline-N-oxide 1,3-Butadiene N-Nitrosodipropylamine 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhiP -
free base & HCl salt)
7,12-Dimethylbenz[a]anthracene 2-Amino-3,4-dimethylimidazo[4,5-f]
quinoline (MeIQ)
Acrylonitrile
Acrylamide Benzo[a]pyrene
Ethyl methanesulphonate Chlorambucil
Mitomycin C Urethane
N-Nitroso-N-methylurea
Procarbazine HCl (natulan)/procarbazine
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negative consistently lowered all of the measures of statistical
agreement (Table 9). This suggests that the equivocal calls might
describe compounds which cause liver DNA damage that is chal-
lenging to detect using the comet assay (e.g. lack of reproducibility
across laboratories or across experimental variables such as route of
administration).• Considering equivocal calls in the bone marrow as positive in-
creased the level of agreement between comet and TGR outcomes:
whereas, considering them as negative reduced the level of agree-
ment as for the liver.• In contrast, the opposite was observed when equivocal calls were
included in the statistical analyses for the stomach. These statistical
results showed better agreement when equivocal results were con-
sidered negative, which is contrary to the expectation stated above.
This result could be a consequence of the very small stomach data
set (Tables 7 and 8).• “Bracketing” the results by counting all equivocal calls as either
positive or negative suggests that resolving each equivocal call into
a positive or negative call would not likely change the conclusions
drawn about results in liver, but could have led to a conclusion of
some level of agreement between the two assays in bone marrow, or
to a conclusion of lack of agreement between the two assays in
stomach.• While the curation exercise resulted in a more refined data set, it
had the consequence of reducing the size of data sets for analysis;
when already small datasets get even smaller, confidence in their
predictive power declines.• A further consideration for strength of the curated stomach and
colon data sets is that there are no negative comet data (Table 7),
which increases the chance that prevalence bias reduces confidence
in the result.
5. Discussion and conclusions
The key question that drove the construction of this database was
whether it is necessary to follow up a chemical that has been shown to
be mutagenic in vitro with an in vivo gene mutation assay (TGR test), or
whether it might be equally acceptable to conduct an in vivo comet
assay. The decision on which of these two approaches to use is related
to the ultimate purpose of the in vivo follow-up test. Accordingly, if the
intention is to confirm in vitro gene mutation activity in terms of gen-
otoxicity in general, then the comet assay is an acceptable choice;
however, if the intention is to confirm specifically that an in vitro gene
mutagen induces in vivo gene mutations per se, then the TGR assay is the
more appropriate test.
In general, from the analyses performed herein using either WoE
evaluation of all the publications or evaluation of a subset of a priori
curated data, the comet assay appears to yield similar results to the TGR
assay in liver. The WoE analysis of aggregate GI tract data also showed
statistical agreement for the comet and TGR assay outcomes. However,
while analysing the curated stomach and colon data separately with the
same statistical approaches showed a similar outcome, the confidence
intervals were wider, thus reducing the reliability of the conclusions for
those tissues. For bone marrow, neither the WoE nor data curation
exercises showed sufficient agreement between the two assays.
There were a number of results considered to be equivocal (E), i.e.
not clearly positive or negative. There is no general agreement as to
how, or whether, such results should be included in an evaluation of
test performances. The data curation results were analysed without the
“E” calls, and then separately with “E” calls included with positives and
Table 7
Comparison of TGR and comet assay results using the data curation approach.
A: Liver Data
TGR mutation (Mice and/or Rats)
Result + – Total
Comet (Mice and/or Rats) + 24 1 25
– 4 4 8
Total 28 5 33
B: Stomach Data
TGR mutation (Mice and/or Rats)
Result + – Total
Comet (Mice and/or Rats) + 4 1 5
– 0 0 0
Total 4 1 5
C: Colon Data
TGR mutation (Mice and/or Rats)
Result + – Total
Comet (Mice and/or Rats) + 8 0 8
– 0 0 0
Total 8 0 8
D: Bone Marrow Data
TGR mutation (Mice and/or Rats)
Result + – Total
Comet (Mice and/or Rats) + 5 0 5
– 5 0 5
Total 10 0 10
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then with “E” calls included as negatives, to bracket a range of probable
measures of agreement if results for these chemicals could be defini-
tively resolved as either positive or negative. For liver, inclusion of “E”
calls as positive did not result in a change in the level of agreement;
however, including the “E” calls as negative decreased PABAK and AC1
without altering the overall conclusion (the level of agreement was
reduced from “good” to “moderate”). Furthermore, including “E” calls
as positive for bone marrow increased the level of AC1 agreement from
“poor” to “moderate”. However, the stomach data behaved differently
from the above two tissues; inclusion of “E” calls as positive decreased
(rather than increasing or not changing) PABAK and AC1, resulting in
poor agreement between results in the two assays. Because including
the “E” calls as either positive or negative did not result in a consistent
change in agreement among tissues, at this time it would not be prudent
to view the equivocal results as “likely positive” or “likely negative”.
Further analyses and additional experiments are required to identify the
factors responsible for this variability.
This database was assembled with chemicals that had been tested in
either TGR or comet assays in vivo. While most of the chemicals that had
data across both assays in a specific tissue were positive in each of the
two assays, the workgroup did not analyse combinations of results from
multiple tissues, particularly tissues other than liver, stomach, colon
and bone marrow, into a whole animal “overall call” for each individual
assay. Thus, the only comparisons in this analysis are between comet
and TGR results for the same chemical in the same tissue. There was a
high prevalence of positive calls for chemicals with results in both TGR
and comet assays for liver and GI tract. This pattern was less pro-
nounced for bone marrow. This high prevalence of positive calls was
absent or less obvious when reviewing all the data (not just from che-
micals with both TGR and comet results) from an individual tissue in an
individual assay (i.e. positive and negative results were more evenly
distributed among all 73 chemicals with liver comet data as opposed to
the 35 chemicals with liver data in both comet and TGR assays). As a
consequence, whilst it is possible to reach meaningful conclusions re-
garding the agreement of positive results (i.e. the sensitivity of the
comet assay relative to the TGR assay) in liver and GI tract, it is not
possible to reach meaningful conclusions on the agreement between the
two endpoints for negative results. To achieve this goal, more chemicals
with negative results in both the TGR and comet assays would be re-
quired. It is also possible that our database is biased in favour of potent
genotoxicants, which tend to be more commonly used in published
studies than found during regulatory testing. Potent genotoxicants are
Table 8
Comparison of TGR and comet assay data for rodent tissues when equivocal calls were included in the analysis post data curation.
A: With equivocal calls counted as positive
Liver TGR mutation (Mice and/or Rats)
Result +/E – Total
Comet (Mice and/or Rats) +/E 31 2 33
– 5 4 9
Total 36 6 42
Stomach TGR mutation (Mice and/or Rats)
Result +/E – Total
Comet (Mice and/or Rats) +/E 4 3 7
– 0 0 0
Total 4 3 7
Bone Marrow TGR mutation (Mice and/or Rats)
Result +/E – Total
Comet (Mice and/or Rats) +/E 8 0 8
– 5 0 5
Total 13 0 13
B: with equivocal calls counted as negative
Liver TGR mutation (Mice and/or Rats)
Result + -/E Total
Comet (Mice and/or Rats) + 24 1 25
-/E 11 6 17
Total 35 7 42
Stomach TGR mutation (Mice and/or Rats)
Result + -/E Total
Comet (Mice and/or Rats) + 4 1 5
-/E 0 2 2
Total 4 3 7
Bone Marrow TGR mutation (Mice and/or Rats)
Result + -/E Total
Comet (Mice and/or Rats) + 5 0 5
-/E 8 0 8
Total 13 0 13
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frequently screened out early in product development and thus our
results may be less predictive of the outcome of less potent genotox-
icants that are more commonly submitted for in vivo genotoxicity
testing in a regulatory environment. Unfortunately, the proprietary
data for such compounds is rarely published so it is difficult to establish
the extent to which this bias would affect the choice of test.
The overall calls for the comet assay for two chemicals are worthy of
specific comment since the overall conclusions reached in the above
analyses were different from those reported in the JaCVAM trial [10]:
• 2-acetylaminofluorene (2-AAF) was judged as negative in the liver
and stomach comet assays by the JaCVAM-organized international
validation study [10]. However, this compound was positive in liver
by the oral route as reported by some participating laboratories in
the JaCVAM validation study [see 10]. Moreover, 2-AAF was posi-
tive in other publications following both oral and i.p. routes of ad-
ministration (see references in Supplementary Table 3). Therefore,
by both WoE and data curation approaches, we concluded that for
liver, the comet assay was positive. Regarding stomach data,
JaCVAM judged this compound negative [10]. However, our ana-
lysis included additional published data (see references in Supple-
mentary Table 3) that resulted in a high level of discordance within
the compiled 2-AFF stomach data, which precluded assignment of
an overall positive or negative call in stomach. Hence, by both WoE
and data curation approaches, 2-AAF was given an overall call of
equivocal in stomach.
• 2,6-diaminotoluene was judged as positive by the JaCVAM-orga-
nized international validation study [10] in the liver comet assay.
However, our survey included other published data (see references
in Supplementary Table 3), using methods of adequate quality, that
reported both positive and negative results in liver. Therefore, our
overall call for the comet assay in liver, by both WoE and data
curation approaches, was equivocal.
It is recognised that cytotoxicity (toxicity in the target tissue) could
be a confounding factor in these assays and therefore warrants discus-
sion. Firstly, in studies where positive comet/TGR responses were seen
across several dose levels it is unlikely that tissue toxicity could explain
all of the responses (particularly at middle and low doses where toxicity
would have been much lower than at the highest dose). Secondly, when
performing our expert judgments, most of the results across papers for a
specific chemical agreed with one another across different dose levels,
indicating a level of reproducibility that would not likely be due to
extreme conditions such as tissue toxicity. Furthermore:
• For the TGR assay, while there are a few examples in the literature
where toxicity in the form of induced cell proliferation allows DNA
adducts, which would otherwise not be fixed as gene mutations (for
the given dose and study design), to become full-fledged gene mu-
tations, this is not regarded as a wide-spread problem with the
assay. Rather, if anything, it increases the sensitivity of the assay to
detect genotoxic agents (see [34,35]). It should be noted that there
Table 9
A comparison of statistical analyses for liver, stomach and bone marrow after data curation.
A: Liver
Table Sensitivity#(95% CI) PI BI Kappa (95% CI) PABAK (95% CI) AC1 (95% CI)
+ve and –ve 0.86 (0.72-0.99) 0.61 0.09 0.53c(0.20e-0.85) 0.70b(0.45c-0.86) 0.78b(0.57c-0.99)
E calls+ ve 0.86 (0.74-0.97) 0.64 0.07 0.44c(0.14e-0.73) 0.67b(0.43c-0.86) 0.76b(0.58c-0.95)
E calls -ve 0.69 (0.53-0.84) 0.43 0.24 0.35d(0.09e-0.60) 0.43c(0.14e-.71) 0.51c(0.24d-0.79)
B: Stomach
Table Sensitivity#(95% CI) PI BI Kappa (95% CI) PABAK (95% CI) AC1 (95% CI)
+ve and –ve 0.80 (0.35-1.00) 0.80 0.20 NA 0.60c(-0.20f-1.00) 0.75b(0.03e-1.00)
E calls+ ve 0.57 (0.13-1.00) 0.57 0.43 NA 0.14e(-0.43h-0.71) 0.35d(-0.59h-1.00)
E calls -ve 1.00 (0.42*-1.00) 0.29 −0.14 0.70b(-0.01f- 1.00) 0.71b(0.14e-1.00) 0.74b (0.11e-1.00)
C: Colon
Table Sensitivity#(95% CI) PI BI Kappa (95% CI) PABAK (95% CI) AC1 (95% CI)
+ve and –ve 1.00 (0.63*-1.00) 1.00 0.00 NA 1.00a(0.63*,b-1.00) 1.00a(0.63*,b-1.00)
D: Bone Marrow
Table Sensitivity#(95% CI) PI BI Kappa (95% CI) PABAK (95% CI) AC1 (95% CI)
+ve and –ve 0.50 (0.14-0.86) 0.50 0.50 NA 0.00f(-0.60h-0.60) 0.20e(-0.60h-1.00)
E calls +ve 0.62 (0.31-0.92) 0.62 0.38 NA 0.23d(-0.23g-0.69) 0.44c(0.58h-0.95)
E calls -ve 0.38 (0.08-0.69) 0.39 0.62 NA −0.23g(-0.69i-0.34) −0.07e(-0.80i-0.65)
CI= confidence interval.
PI= prevalence index.
BI= bias index.
# = ability of the comet assay to detect TGR positives.
* = Clopper-Pearson Lower Limit.
a = very good agreement (0.81–1.00)f= some disagreement (0 to -0.20).
b = good agreement (0.61-0.80) g= fair disagreement (-0.21 to -0.40).
c = moderate agreement (0.41-0.60) h=moderate disagreement (-0.41 to –0.60).
d = fair agreement (0.21-0.40)i= substantial disagreement (-0.61 to -0.80).
e = poor agreement (< 0.20).
f = some disagreement (0 to -0.20).
g = fair disagreement (-0.21 to -0.40).
h = moderate disagreement (-0.41 to –0.60).
i = substantial disagreement (-0.61 to -0.80).
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is no requirement in the OECD test guideline to examine cytotoxicity
in the tissues being examined, and as such, it is rarely conducted. A
vast majority of the TGR studies in our database were conducted
over the duration of 1-month, and de novo tissue proliferation could
be a confounding factor. However, to the best of our knowledge,
during 1-month of daily dose administration, observing tissue re-
generation in liver or GI tract is a rare event, and this observation
was not detailed in the discussion section of the papers included in
the database.• For the comet assay, it was rare to find reports of histopathology
analysis in published papers before the last few years, yet the cur-
rent OECD test guideline relied heavily on that early literature. We
do not believe it would be appropriate to reject data in the literature
for no other reason than there was no explicit measurement of organ
toxicity. It was fairly rare to find older comet studies with more than
one or two days of dosing, and it is unclear what data would be used
to accurately predict toxicity in such an acute study. An acute
toxicity study rarely provides much information about specific
organ toxicity and it is unclear how the results from a longer-term
repeat dose study would be used to predict a dose that was (in)
appropriate for administration of the chemical one to three times
over a day or two.
Hence, we believe that in the majority of the studies reviewed here,
cytotoxicity was not a confounding factor. On the rare occasions we did
see signs of toxicity, we explicitly used that as one of the criteria for
Table 10
Lists of chemicals with overall positive /negative calls in both TGR and comet assays (data curation approach).
A: Liver
TGR +/ comet + (24) TGR +/comet – (4) TGR -/ comet + (1) TGR -/comet – (4)
1-Ethyl-1-nitrosourea 4-Aminobiphenyl (free base + HCL salt) Ethyl acrylate Allura Red AC (Food Red 40)
2-Acetylaminofluorene Chlorambucil Chloroform
2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhiP - free base & HCl
salt)
Chromium (hexavalent) Hydroquinone
2-Amino-3,4-dimethylimidazo[4,5-f]quinoline (MeIQ) Methyleugenol Methylphenidate HCl
2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx)
2-Amino-3-methylimidazo[4,5-f]quinoline (IQ - free base & HCL salt)
5,9-Dimethyldibenzo[c,g]carbazole
Acrylamide
Aflatoxin B1
Aristolochic acids I and II (and sodium salt)
beta-Propiolactone
Cisplatin
Cyclophosphamide (free base and monohydrate)
Cyproterone acetate
Dichlorvos
Dicyclanil
N-Nitrosodiethylamine (diethylnitrosamine)
N-Nitrosodimethylamine (dimethylnitrosamine)
N-Nitrosodipropylamine [dipropylnitrosamine]
N-Nitroso-N-methylurea
N-Nitrosopyrrolidine
Procarbazine HCl (natulan)/procarbazine
Urethane
Wyeth 14,643
B: Stomach and colon
Stomach
TGR +/ comet + (4) TGR +/comet – (0) TGR -/ comet + (1) TGR -/comet – (0)
4-Nitroquinoline-N-oxide Ethyl acrylate
Benzo[a]pyrene
beta-Propiolactone
N-Methyl-N'-nitro-N-nitrosoguanidine
Colon
TGR +/ comet + (8) TGR +/comet – (0) TGR -/ comet + (0) TGR -/comet – (0)
1-Ethyl-1-nitrosourea
2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhiP - free base & HCl salt)
2-Amino-3,4-dimethylimidazo[4,5-f]quinoline (MeIQ)
2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx)
2-Amino-3-methylimidazo[4,5-f]quinoline (IQ - free base & HCL salt)
7,12-Dimethylbenz[a]anthracene
Benzo[a]pyrene
C.I. Solvent yellow 3 (o-aminoazotoluene)
C: Bone marrow
TGR +/ comet + (5) TGR +/comet – (5) TGR -/ comet + (0) TGR -/comet – (0)
4-Nitroquinoline-N-oxide 1,3-Butadiene
Aristolochic acids I and II (and sodium salt) 2-Amino-3,4-dimethylimidazo[4,5-f]quinoline (MeIQ)
Mitomycin C Benzo[a]pyrene
N-Nitroso-N-methylurea Chlorambucil
Procarbazine HCl (natulan)/procarbazine Urethane
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potential exclusion. Thus, in papers where histological findings or other
cytotoxicity information was available (only a few papers), we down-
graded the findings in that tissue. However, by and large we saw
nothing that would lead us to conclude it was an important con-
founding factor. Therefore, overall, we do not believe the possible
confounding effects of tissue toxicity invalidates the comparisons we
have made or the conclusions we have reached.
Because the two OECD Test Guidelines were published within the
last 10 years, and after most of the data leading to their adoption was
collected, most of the available data (used in the current analysis) was
collected using protocols not consistent with the OECD guidelines. For
example, dosing periods tended to be too short for many TGR studies
and histopathology was not used to evaluate cytotoxicity in many
comet studies. The experts reviewing these studies identified those
protocol deficiencies and indeed many results were removed during
study collection, data curation and WoE analyses due to those factors.
However, most of these data were non-GLP studies using varied pro-
tocols and those factors make the conclusions less reliable than would
be drawn if sufficient results had been available from more recent,
guideline compliant studies.
There were a number of results considered to be equivocal (E), i.e.
not clearly positive or negative. There is no general agreement as to
how, or whether, such results should be included in an evaluation of
test performances. In order to simplify the analyses based on the total
publications in the data entry spreadsheets, equivocal and inconclusive
results were excluded from the WoE analyses and only positive and
negative overall calls were analysed.
Analysis of TGR and comet results could be carried out for tissues
other than those reported here by further interrogating the results in the
final 91 chemical database, as well as the results tabulated in the data
entry spreadsheets. Further analysis of how TGR and comet assays re-
spond to in vitro gene mutagens and mutagenic (genotoxic) carcinogens
is on-going, and will be reported elsewhere [36]. The outcome of those
analyses may allow more specific recommendations on follow-up
testing for regulatory purposes. Our database may also provide oppor-
tunities for additional analyses, such as reproducibility of comet and
TGR data across laboratories, concordance of results across species,
difference in results due to route of administration, and investigating
the degree of agreement in responses across tissues (or combinations of
tissues) other than those analysed here. Data curation, by removing
studies of lower quality, will make such comparisons more reliable and
less subject to distortion due to results from repeatedly testing the same
potent genotoxicants. Such analyses may provide crucial insight into
the choice of which assays to conduct to provide the most robust eva-
luation of genotoxicity in rodents.
The general conclusion that can be drawn from the analyses of this
database is that the comet assay can detect potent genotoxicants that
would otherwise be detected using the TGR assay in the liver, and GI
tract; however, confidence in this GI tract association is reduced if se-
parate regions are considered. In contrast, the bone marrow data sug-
gests that one cannot expect the two assays to give the same result in
every tissue. Assay concordance for genotoxicants which induce weak
responses is less certain since our database contained fewer such che-
micals. The conclusions contained herein will be of interest to reg-
ulatory agencies and laboratories during the process of selecting in vivo
genotoxicity assays and tissues to test.
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